Networks in Neurology: Insights From a Collaborative CME Experience With Practicing Clinicians Regarding New Agents and Strategies for Multiple Sclerosis
Program DescriptionMultiple sclerosis (MS) management has been evolving at a staggering rate for the past two decades, with nearly a third of the 21 available disease modifying therapies (DMTs) receiving their FDA approvals in just the past few years.
Category
Format
Credits
Devil in the Details: An Expert Guide to Modern Multiple Sclerosis Practices (Credit Expired)
Program DescriptionThis activity is designed to highlight the differences in self-reported diagnostic and therapeutic strategies of MS specialists and general neurologists.
Category
Format
Credits
The Path of Least Resistance: New Agents and Emerging Strategies for Managing Childhood-Onset and Refractory Epilepsies (Credit Expired)
Program DescriptionEpilepsy syndromes are historically difficult to diagnose and treat effectively due to their widely varying etiologies and presentations and their high probability of drug-resistance.
Category
Format
Credits
Why Now? The New Paradigm and Rising Role of Nuclear Medicine in Alzheimer’s Disease (Credit Expired)
OverviewWith the field’s increasing understanding of and ability to manipulate the complex networks of amyloid and tau that drive Alzheimer’s disease (AD), the value of directly visualizing their activity is exponentially rising.
Category
Format
Credits
Finding Something in Nothing: Patient-Centered Approaches to Resolve Emotional Blunting in Major Depressive Disorder (Credit Expired)
Program Description Emotional blunting (EB) is one of the most highly reported and subjectively disruptive symptoms in patients with major depressive disorder (MDD).
Category
Format
Credits
Understanding the Fine Print: The Who, When, And What To Do About ARIA in Patients with Alzheimer’s Disease - Introductory Module
Program DescriptionRecently, Alzheimer’s Disease (AD) saw its first approvals for disease-modifying therapy (DMT). With amyloid-beta (Aβ) targeting DMT now a reality, the entire way this condition is viewed and managed is changing.
Category
Format
Credits
  • 0.50 AAPA Category I CME
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Attendance
Understanding the Fine Print: The Who, When, And What To Do About ARIA in Patients with Alzheimer’s Disease - Radiology Module
Category
Format
Credits
  • 0.50 AAPA Category I CME
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Attendance
Understanding the Fine Print: The Who, When, And What To Do About ARIA in Patients with Alzheimer’s Disease - Closing Module
Program DescriptionRecently, Alzheimer’s Disease (AD) saw its first approvals for disease-modifying therapy (DMT). With amyloid-beta (Aβ) targeting DMT now a reality, the entire way this condition is viewed and managed is changing.
Category
Format
Credits
  • 0.50 AAPA Category I CME
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Attendance
Understanding the Fine Print: The Who, When, And What To Do About ARIA in Patients with Alzheimer’s Disease - Neurology Module
Category
Format
Credits
  • 0.50 AAPA Category I CME
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Attendance
Overburdened, Undertreated: Developments in the Patient-Centered Management of Spasticity in Multiple Sclerosis
Program DescriptionOver 80% of patients with multiple sclerosis (MS) experience related spasticity.
Category
Format
Credits
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 Attendance

Pages